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Risk Adjusted Mortality
Ratings and Public
Reporting for High-Risk PCIWe appreciate the perspective of the comments by Drs.
Miner andNield (1) regarding our study (2). As noted byDrs. Miner and Nield (1), there are many limitations to
any form of observational risk-adjusted outcomes
comparisons. Certainly cardiac arrest or shock patients
have a gradient of risk, and certainly providers may
have a gradient in who they take to the lab or how they
classify and report “high risk.” In individual cases, a
provider could overcall shock in a lower-risk case and
thereby have better observed results than expected.
However, the American College of Cardiology–NCDR
(National Cardiovascular Data Registry) risk models
were developed from real-world data. As such,
provider-related factors would have already been
incorporated into the models. Thus, such variation in
community practice is unlikely to explain why, in
aggregate, providers who take on more high-risk cases
do better. More importantly, in our analyses of the
“concentrated risk year,” we used the individual pro-
viders themselves as their own control group. We
found in such high-risk scenarios, providers’ “risk-
adjusted” outcome performance was as good or better
in high-risk cases than when the provider faced
normal-risk or low-risk groups. So, we believe our
paper provides compelling evidence that, in aggre-
gate, the NCDR percutaneous coronary intervention
risk models adequately assess and compensate pro-
viders for taking high-risk cases to the lab.
However, Miner and Nield (1) also raise an impor-
tant point regarding whether or not public reporting
itself is harmful or helpful. To be clear, our paper
should not be seen as an endorsement of public
reporting, and we agree the assessment of the total
impact of public reporting is complex. On the one
hand, public reporting does provide consumers with
information on provider outcomes as well as give
providers an incentive to monitor and hopefully
improve their procedural outcomes. Although there is
much debate whether consumer choice is improved
via public reporting, there has been consistent evi-
dence supporting the value of performance mea-
surement and subsequent provider-led quality
improvement, including door-to-balloon times, as
well as with the outcomes of acute myocardial
infarction, heart failure (3), and stroke (4). On the
other hand, public outcome reporting could make
certain providers “gun shy” and unwilling to take
high-risk cases to the lab, even in situations where
revascularization may be beneﬁcial (such as ST-
segment elevation myocardial infarction or shock).
Previous studies have indicated that states with
public reporting use PCI less and perhaps have worse
outcomes than do states without (5). However, these
studies were the exact motivation for our paper. Risk-
averse clinician behavior likely represents the pro-
vider’s fear that taking on high-risk cases will “hurt”
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 8 , 2 0 1 5 Letters to the Editor
J U L Y 2 0 1 5 : 1 1 2 9 – 3 7
1135their performance ratings relative to peers. Our data
demonstrate that such fears appear unfounded.
In conclusion, although one can debate the impacts
of public reporting, our study should be interpreted
to say that if it is undertaken, current modeling
methods are generally adequate to capture and adjust
for case mix and risk and thereby avoid penalizing
clinicians who take on high-risk patients. We hope
such information encourages providers to think more
about the outcomes of their high-risk patients than
about the impact of these on their procedural report
card results.*Matthew W. Sherwood, MD, MHS
Eric D. Peterson, MD, MPH
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Uncertain Detection of
Nonuniform Scaffold
Expansion Patterns Using
Optical Coherence
TomographyWe read with interest the paper by Ohno et al. (1)
and found that their conclusions merit a few com-
ments. Longitudinal nonuniform expansion pat-
terns by the ABSORB bioresorbable scaffold (BVS)
(Abbott Vascular, Irvine, California) may be of clinicalimportance, but the use of optical coherence tomog-
raphy (OCT) to identify such patterns requires
methods that take catheter motion artifacts into ac-
count. The variation in length measurements by OCT
compared with nominal length has been reported in
ABSORB BVS–treated patients with differences of as
much as 5.2 mm (2) and as much as 10 mm in metal
stent–treated patients (3), although stent indepen-
dent. The OCT-evaluated lengths also showed varia-
tion within the same scaffold at different time points
(2), indicating that OCT may not be appropriate as a
criterion standard for intravascular length measure-
ments. Variation in length occurs in subsegments and
may cause visible motion artifacts of elongation and
compression at each heartbeat. Faster pullback sys-
tems (36 mm/s, OPTIS Integrated System, St. Jude
Medical, St. Paul, Minnesota; 40 mm/s, LUNAWAVE,
Terumo, Tokyo, Japan) reduce the impact of motion
artifacts (4), and a prototype system enabling long
pullbacks at 100 mm/s “in one heartbeat” has been
reported (5).
The 3-dimensional (3D) OCT reconstructions shown
by Ohno et al. might call for a different interpreta-
tion because the “elongated” scaffold (Figure 1D)
actually looks partially longitudinally compressed,
also when compared with the “normal” scaffold
(Figure 1H). Further, the struts of the BVS in Figure 1D
in both ends seem affected by fracture, mo-
tion artifacts, or an oblique imaging wire position.
To rule out catheter motion artifacts as the ex-
planation of potential scaffold compression or
elongation, it is advisable to compare 3D OCT re-
constructions of at least 2 subsequent pullbacks of the
same section.
The reported ﬁnding of differences in strut thick-
ness may call for a more systematic workup because a
mean strut thickness reduction of 15 mm (9.6%) by the
suggested length increase of 2.6 mm (14.4%) is ques-
tionable. When deployed, the scaffold adapts to
the vessel wall by changing angulations within the
sinusoidal hoops and connectors, and because the
hoops in Figure 1D are not straightened fully by dila-
tion or drag from the connectors, a substantial reduc-
tion in thickness due to elongation of the scaffold is
unlikely. If the reduction in strut thickness is real,
struts in the hoops might have been stretched locally
by the higher deployment pressure, but this is still
uncertain because the hoops are not fully extended
in the 3D reconstruction. Although not previously
reported, struts might also have been squeezed by
the higher deployment pressure, but subtle produc-
tion differences between the 2 sizes of the ABSORB
scaffold might also have caused a potential difference
in strut thickness. However, explanations may also
